These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 39168375

  • 1. Interferon alpha induces a stronger antiviral effect than interferon lambda in HBV/HDV infected humanized mice.
    Duehren S, Uchida T, Tsuge M, Hiraga N, Uprichard SL, Etzion O, Glenn J, Koh C, Heller T, Cotler SJ, Oka S, Chayama K, Dahari H.
    Virus Res; 2024 Nov; 349():199451. PubMed ID: 39168375
    [Abstract] [Full Text] [Related]

  • 2. Both interferon alpha and lambda can reduce all intrahepatic HDV infection markers in HBV/HDV infected humanized mice.
    Giersch K, Homs M, Volz T, Helbig M, Allweiss L, Lohse AW, Petersen J, Buti M, Pollicino T, Sureau C, Dandri M, Lütgehetmann M.
    Sci Rep; 2017 Jun 16; 7(1):3757. PubMed ID: 28623307
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139-Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection.
    Bazinet M, Pântea V, Cebotarescu V, Cojuhari L, Jimbei P, Anderson M, Gersch J, Holzmayer V, Elsner C, Krawczyk A, Kuhns MC, Cloherty G, Dittmer U, Vaillant A.
    Hepatol Commun; 2021 Feb 16; 5(2):189-202. PubMed ID: 33553968
    [Abstract] [Full Text] [Related]

  • 10. Hepatitis Delta co-infection in humanized mice leads to pronounced induction of innate immune responses in comparison to HBV mono-infection.
    Giersch K, Allweiss L, Volz T, Helbig M, Bierwolf J, Lohse AW, Pollok JM, Petersen J, Dandri M, Lütgehetmann M.
    J Hepatol; 2015 Aug 16; 63(2):346-53. PubMed ID: 25795587
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Screening for hepatitis D and PEG-Interferon over Tenofovir enhance general hepatitis control efforts in Brazil.
    Goyal A, Romero-Severson EO.
    PLoS One; 2018 Aug 16; 13(9):e0203831. PubMed ID: 30192887
    [Abstract] [Full Text] [Related]

  • 19. Guanylate-Binding Protein 1 (GBP1) Enhances IFN-α Mediated Antiviral Activity against Hepatitis B Virus Infection.
    Li Y, Luo H, Hu X, Gong J, Tan G, Luo H, Wang R, Pang H, Yu R, Qin B.
    Pol J Microbiol; 2024 Jun 01; 73(2):217-235. PubMed ID: 38905278
    [Abstract] [Full Text] [Related]

  • 20. HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta.
    Sandmann L, Yurdaydin C, Deterding K, Heidrich B, Hardtke S, Lehmann P, Bremer B, Manns MP, Cornberg M, Wedemeyer H, Maasoumy B, HIDIT‐II Study Group.
    Hepatol Commun; 2022 Mar 01; 6(3):480-495. PubMed ID: 34561972
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.